Trial
NCT01290887
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Collaborators
—
Condition
Eosinophilic Asthma
Intervention
Reslizumab
Why stopped
Business decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-06-06